19 stories mentioning GH
Every FINWIRES story that references GH, newest first.
Guardant Health (GH) has an average rating of buy and mean price target of $143.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks were higher premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining 0.3% and the iShares Biotechnology ETF (IBB) advancing 0.1%.Novartis (NVS) stock was up more than 2% premarket after the company said a phase 1/2 study of its experimental therapy, del-brax, met both primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy.Guardant Health (GH) shares gained more than 1% pre-bell after the company said the US Food and Drug Administration has approved Guardant360 CDx for Boehringer Ingelheim's Hernexeos in adults with HER2-mutant advanced non-small cell lung cancer.Tilray Brands (TLRY) stock advanced 0.6% after its BrewDog unit said it is reducing pint prices to 2 UK pounds ($2.67), or about 1998 levels, at its Scottish bars for an upcoming 72-hour bank holiday weekend.
Guardant Health (GH) said Thursday that the US Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's Hernexeos therapy in adults with HER2-mutant advanced non-small cell lung cancer.The Guardant360 CDx is a liquid biopsy test that identifies patients with HER2 mutations who may be eligible for treatment with Hernexeos, Guardant Health said.Shares of the company were up 1.6% in Thursday premarket trading.
Helmy Eltoukhy, Director, Co-Chief Executive Officer, on June 05, 2026, sold 100,000 shares in Guardant Health (GH) for $12,629,969. Following the Form 4 filing with the SEC, Eltoukhy has control over a total of 2,012,919 common shares of the company, with 2,012,919 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000175296826000010/xslF345X05/wk-form4_1780957766.xml
Guardant Health (GH) has an average rating of overweight and mean price target of $134.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
John G. Saia, Chief Legal Officer, on May 27, 2026, sold 10,000 shares in Guardant Health (GH) for $1,250,836. Following the Form 4 filing with the SEC, Saia has control over a total of 35,950 common shares of the company, with 35,950 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000173784026000014/xslF345X05/wk-form4_1780007559.xml
Healthcare stocks rose late Wednesday afternoon with the NYSE Healthcare Index gaining 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, BioNTech's (BNTX) cancer-drug pipeline is showing stronger early results and is approaching several important clinical milestones, improving confidence in the company's long-term outlook, UBS Securities said. BioNTech shares rose 1.4%.Corcept Therapeutics (CORT) shares jumped 9.7% after the company said it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome.Boston Scientific (BSX) shares slumped 12% after CEO Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.2%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Corcept Therapeutics (CORT) shares jumped past 6% after the firm said Wednesday it will resubmit its new drug application to the US Food and Drug Administration in the coming weeks for relacorilant to treat Cushing's syndrome, also known as hypercortisolism.Boston Scientific (BSX) shares slumped 12% after Chief Executive Mike Mahoney said this year has been "a bit more of a challenge" than anticipated.Guardant Health (GH) shares gained 5.8% after the firm said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively traded Invesco QQQ Trust (QQQ) was 1.7% higher in Wednesday's premarket activity amid all-time highs achieved by the S&P 500 and the Nasdaq along with continued optimism for an end to the Middle East conflict.US stock futures were higher, with S&P 500 Index futures up 0.3%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.7% before the start of regular trading.The Richmond Federal Reserve's manufacturing and business conditions readings for May are due to be released at 10 am ET, followed by the Dallas Fed's non-manufacturing survey for May at 10:30 am ET.Mortgage applications fell by 8.5% in the week ended May 22 as a sharp increase in mortgage rates pushed down refinancing activity and new home applications, according to Mortgage Bankers Association data released Wednesday.In premarket activity, bitcoin was down by 0.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.2% higher, Ether ETF (EETH) advanced 2.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) increased by 0.2%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 1.5%, while the Vanguard Industrials Index Fund (VIS) gained 1.7%, and the iShares US Industrials ETF (IYJ) rose 1.3%.Dycom Industries (DY) stock was up more than 23% before the opening bell after the company reported higher fiscal Q1 adjusted net income and contract revenue.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) dropped 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.3%, while Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% higher.Qfin (QFIN) stock was up more than 7% even after the company posted lower Q1 non-GAAP net income and net revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 1.4% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) dropped by 1.4%. The iShares US Consumer Staples ETF (IYK) retreated by 1.6%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased by 0.2%. The VanEck Retail ETF (RTH) was 1.2% lower, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% higher.PDD Holdings (PDD) shares were down more than 7% after the company posted Q1 non-GAAP earnings and revenue that missed analysts' estimates, with non-GAAP EPS declining year over year.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) increased by 2.6%, and the iShares US Technology ETF (IYW) was 2.3% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 2.4%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained by 4.7%, while the iShares Semiconductor ETF (SOXX) rose by 6.1%.Micron Technology (MU) shares were up more than 7%, extending gains after the company's market capitalization eclipsed $1 trillion for the first time on Tuesday.EnergyThe iShares US Energy ETF (IYE) was 2.5% lower, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 2.7%.TotalEnergies (TTE) is facing a dispute with Mozambique over about $2 billion in costs tied to delays at its liquefied natural gas project in the country, Bloomberg reported, citing an unnamed person familiar with the matter. Shares of TotalEnergies were down more than 2% pre-bell.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.9%, the Vanguard Health Care Index Fund (VHT) was up 0.7%, while the iShares US Healthcare ETF (IYH) lost by 0.7%. The iShares Biotechnology ETF (IBB) was 0.4% higher.Guardant Health (GH) shares were up more than 5% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.CommoditiesFront-month US West Texas Intermediate crude oil fell by 5.6% to $88.54 per barrel on the New York Mercantile Exchange. Natural gas was up 1.8% at $2.95 per 1 million British Thermal Units. The United States Oil Fund (USO) retreated by 2.7%, while the United States Natural Gas Fund (UNG) was 0.3% lower.Gold futures for August retreated by 1.6% to $4,461.50 an ounce on the Comex. Silver futures fell by 2.9% to $74.35 an ounce. SPDR Gold Shares (GLD) was up by 0.04%, and the iShares Silver Trust (SLV) rose by 2%.
Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% lower and the iShares Biotechnology ETF (IBB) up 0.5%.Guardant Health (GH) shares were up more than 5% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.TG Therapeutics' (TGTX) Phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure between the approved two-infusion initiation regimen for Briumvi and a proposed single Day 1 infusion dosing schedule, the company said. TG Therapeutics stock was up more than 1% pre-bell.Nuvalent (NUVL) shares were up more than 1% after the company said the US Food and Drug Administration accepted for filing its New Drug Application for neladalkib, an investigational ALK-selective inhibitor in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.
Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% lower and the iShares Biotechnology ETF (IBB) up 0.7%.Guardant Health (GH) shares were up more than 6% after the company said its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines.
Chris Freeman, Chief Commercial Officer, on May 22, 2026, sold 24,406 shares in Guardant Health (GH) for $2,896,360. Following the Form 4 filing with the SEC, Freeman has control over a total of 60,034 common shares of the company, with 60,034 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000187161526000010/xslF345X05/wk-form4_1779831478.xml
Ian T Clark, Director, on May 20, 2026, sold 6,876 shares in Guardant Health (GH) for $735,049. Following the Form 4 filing with the SEC, Clark has control over a total of 2,975 common shares of the company, with 2,975 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000133650426000002/xslF345X05/wk-form4_1779483443.xml
AmirAli Talasaz, Director, Co-Chief Executive Officer, on May 20, 2026, sold 210,000 shares in Guardant Health (GH) for $23,076,690. Following the Form 4 filing with the SEC, Talasaz has control over a total of 1,886,504 common shares of the company, with 1,886,504 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000175315926000012/xslF345X05/wk-form4_1779483475.xml
John G. Saia, Chief Legal Officer, on May 20, 2026, sold 20,000 shares in Guardant Health (GH) for $2,130,229. Following the Form 4 filing with the SEC, Saia has control over a total of 45,950 common shares of the company, with 45,950 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000173784026000012/xslF345X05/wk-form4_1779483506.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $28 to $140, reflecting a 9.6x multiple of our 2026 EV/sales estimate, below GH's one-year historical forward average of 10.6x and above the three-year forward average of 7.6x. We narrow our 2026 loss per share estimate by $0.01 to -$1.42 and narrow 2027's by $0.12 to -$0.62. We think GH's strengthening growth outlook gains support from yesterday's FDA approval of the updated Guardant360 Liquid CDx test, which incorporates a 100x greater genomic footprint than the previous version and supports significantly greater tumor sensitivity, with a rapid turnaround time of just seven days. We think the approval may expand GH's addressable market and support higher testing volumes, supported by recent momentum from partnerships with pharma and lab testing firms, while potentially accelerating GH's path toward profitability (anticipated around late 2027 to early 2028).
AmirAli Talasaz, Director, Co-Chief Executive Officer, on May 12, 2026, sold 50,000 shares in Guardant Health (GH) for $5,016,000. Following the Form 4 filing with the SEC, Talasaz has control over a total of 2,096,504 common shares of the company, with 2,096,504 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1576280/000175315926000010/xslF345X05/wk-form4_1778707917.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Guardant Health delivered one of its strongest quarters with Q1 sales surging 48% to ~$302M, well above the $279M consensus estimate, driven by oncology testing volumes of 86K tests (+47% Y/Y) and screening revenue jumping over 600%. Oncology sales grew 36% to $205M while Shield screening revenue reached $41.6M vs. $5.7M in the prior year, with Shield volumes of ~44K up nearly 400% Y/Y. We believe the recently announced nationwide Quest Diagnostics collaboration supports Shield's momentum and strengthens the growth trajectory. Following these strong results, management raised 2026 sales growth guidance to a 33% midpoint from 28.5% previously. Adjusted gross margin improved to 66% from 65% despite significant volume growth, demonstrating operational leverage. We expect continued acceleration in Shield adoption and oncology volume growth to drive sustained revenue expansion, supported by expanding reimbursement coverage and the Quest partnership enhancing market penetration.
Guardant Health (GH) said Monday the US Food and Drug Administration approved its Guardant360 CDx test as a companion diagnostic for Arvinas (ARVN) and Pfizer's (PFE) Veppanu for certain breast cancer patients.The company said the blood-based test identifies ESR1 mutations in patients with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer who may be eligible for treatment with Veppanu following prior endocrine therapy.Guardant Health said this marks its third FDA approval for an ESR1 companion diagnostic and brings the total number of approved uses for the test across cancer types to 26.Price: $87.88, Change: $+0.28, Percent Change: +0.32%